ModifiedPremera BluecrossPolicy N/A

Hereditary angioedema drug coverage and site-of-service criteria

Defines medical necessity, site-of-service review, and coverage criteria for drugs used to treat hereditary angioedema (HAE) for Premera members, including age and laboratory requirements and administration settings.

Policy Summary

PayerPremera Bluecross

PolicyHereditary angioedema drug coverage and site-of-service criteria

Policy CodePolicy N/A

Change TypeMaterial updates to coverage criteria, step-therapy, age indications, and site-of-service exceptions

Effective DateOct 3, 2025

Next Review DateN/A

Key ActionSubmit prior authorization with office visit notes and laboratory results (low C4 and C1‑INH testing) to document medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated Takhzyro coverage criteria from individuals 12 years of age and older to individuals 2 years of age and older.

Removed requirement to try danazol or another androgen for adult males from Haegarda, Orladeyo, Takhzyro, and Cinryze.

Added a requirement to trial generic icatibant (or Sajazir) before coverage for Berinert, Kalbitor, and Ruconest for acute attacks (with age and pregnancy clarifications added later).

Site of Service Medical Necessity criteria do not apply to Alaska fully-insured members per Alaska HB 226, and site-of-service rules clarified to possibly apply to injection drugs with exceptions for CRS.

Added coverage for new drugs (Andembry, Dawnzera) for long-term prophylaxis and Ekterly for acute attacks, plus associated HCPCS updates in future-effective history entries.

Multipledrugs listed for review (acute and prophylaxis)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for HAE Therapies

inv-01: Drug-specific medical necessity (acute treatment and long-term prophylaxis)

Covered when ALL of the following are met for the specified drug and indication

Laboratory confirmation: Documented laboratory values consistent with HAE: low complement component 4 (C4) and low C1‑INH antigenic levels for type I; low C4, normal/high C1‑INH antigenic and low C1‑INH functional levels for type II; acquired angioedema requires low C1q in addition.lab values as specified by drug

'Low' defined as below the laboratory lower limit of normal

Clinical features: Has two or more of the following: recurrent angioedema without wheals/urticaria; recurrent abdominal attacks; positive family history of HAE; failure to respond to antihistamines, glucocorticoids, or epinephrine.2 features

Additional qualifying conditions: One of: history of ≥1 HAE attack per month over a 6‑month period requiring acute treatment with listed agents; documentation of pregnancy; documentation of a laryngeal HAE attack within the last 5 years.1 of the list

Concomitant therapy restriction: Treatment is not used concomitantly with other targeted HAE‑specific therapies for the same purpose (acute versus prophylaxis, as applicable).no concomitant targeted HAE therapy

Age and dosing limits: Agent‑specific minimum ages and dose limits apply (examples in policy: Cinryze prophylaxis ≥6 years; Ruconest acute ≥13 years with dose limit 150 mg/day; generic icatibant/Firazyr acute ≥18 years for some criteria; Takhzyro prophylaxis ≥2 years; Ekterly maximum 1,200 mg per 24 hours and 2,400 mg per 30 days; Takhzyro dosing 300 mg every 2 weeks).agent-specific

See individual drug entries for exact age and dose limits.

inv-02: Site of Service (SOS) Medical Necessity criteria

Site‑of‑service medical necessity for intravenous/injectable administration (medical benefit reviews only)

Medically necessary sites: Physician office, infusion center, or home infusion are the preferred medically necessary sites for specified IV/SC/injectable drugs when appropriate, safe, and cost‑effective.

Applies to medical benefit reviews; does not apply to Alaska fully‑insured members for SOS per policy history.

Hospital outpatient setting considered medically necessary: Hospital outpatient infusion is considered medically necessary for the initial course or re‑initiation after ≥6 months, when no outpatient infusion center exists within 50 miles and no contracted home infusion agency will travel, or when the individual has clinical conditions increasing infusion risk (e.g., symptomatic cardiac arrhythmia; significant respiratory disease with %FVC ≤40%; unstable renal function; difficult vascular access; acute mental status changes; history of severe adverse drug reactions/anaphylaxis).conditions listed

Policy limits initial hospital‑based course to defined durations in some contexts (see site‑of‑service details).

inv-03: Coverage considerations / preferred therapy

Coverage considerations and guideline‑based preferences that inform initial choice and benefit assignment

Site‑of‑service age criterion: Site‑of‑service medical necessity review is limited to individuals aged 13 years or older due to pediatric administration considerations.>=13 years

Pediatric-specific administration differences justify the age cutoff for SOS review.

Benefit assignment: Drugs are assigned to pharmacy, medical, or both benefits as listed (examples: Ekterly and Orladeyo — pharmacy; Berinert/Cinryze/Ruconest — medical; several agents managed under both pharmacy and medical benefits).

Refer to the coding/benefit application section for full mapping.

Preferred long‑term prophylaxis: WAO/EAACI guidelines recommend C1‑INH products, lanadelumab, and berotralstat as first‑line long‑term prophylaxis; androgens are second‑line and are contraindicated in pregnancy and to be avoided in certain pediatric populations.

inv-04: Step therapy / acute agent sequencing

Coverage is provided with specified step‑therapy requirements and sequencing for some acute and prophylactic agents

Generic icatibant step requirement for certain agents: Prior trial of generic icatibant (historically Sajazir when listed) is required before coverage of Berinert, Kalbitor, and Ruconest for eligible individuals per policy updates.applies to individuals >=18 years who are not currently pregnant (clarified)

Policy history documents the addition and later age/pregnancy clarifications.

Guideline‑based sequencing for prophylaxis: Guideline‑preferred escalation for long‑term prophylaxis: first‑line C1‑INH products, lanadelumab, and berotralstat; androgens reserved as second‑line (avoid in pregnancy and certain pediatric groups).

May inform prior authorization decisions and step requirements.

inv-05: Age-specific coverage

Agent‑specific age indications and limits

Takhzyro (lanadelumab) age indication: Takhzyro coverage criteria updated to include individuals 2 years of age and older.>=2 years

Updated per 2023 prescribing information review.

Haegarda age note: Haegarda prescribing information updated in prior history entries noting use up to 26 years of age in the referenced review.<=26 years as noted

Recorded in 2020 history entry.

inv-06: Site-of-service rules and exceptions

Site‑of‑service rules and documented exceptions

Alaska fully‑insured members exception: Site‑of‑Service Medical Necessity criteria do not apply to Alaska fully‑insured members pursuant to Alaska HB 226; for those members only the infusion/injection drug medical necessity criteria apply.jurisdictional

Added to the policy in 2025 updates and history.

CRS and other clinical exceptions: An exception to site‑of‑service requirements exists for individuals receiving treatment for cytokine release syndrome (CRS) when specified criteria are met; policy also clarifies that site‑of‑service criteria can apply to injection drugs.clinical exception

Clarified in 2025 update.

Per Alaska HB 226, the policy's Site of Service (SOS) Medical Necessity criteria do not apply to Alaska fully-insured members. For those members, refer to the infusion and injection drug medical necessity criteria rather than the SOS review rules. This exception was added in the 2025 policy update and clarifies that the SOS requirements (e.g., preferred sites such as physician office, infusion center, or home infusion versus hospital-based outpatient infusion) are not applied for Alaska fully-insured populations.

Traditional allergy treatments that target mast-cell/histamine-mediated pathways—specifically antihistamines, epinephrine, and corticosteroids—are not effective for acute hereditary angioedema (HAE) attacks and therefore are not appropriate as HAE-specific acute therapy. HAE attacks are mediated primarily by kallikrein/bradykinin pathways rather than histamine, and guideline and policy language note these agents do not provide clinical benefit for HAE acute management.

Policy history documents changes to acute-agent sequencing: a trial of generic icatibant (or Sajazir where previously listed) was required before coverage of certain acute agents. In the 2024 update this requirement was applied to Berinert, Kalbitor, and Ruconest. The 2025 update removed Sajazir as a preferred treatment; the policy continues to reflect the generic icatibant step requirement where applicable and clarifies age and pregnancy-based limitations elsewhere in the criteria.

Hospital-based outpatient infusion (outpatient hospital IV infusion department) is generally reserved for specific circumstances and is considered not medically necessary when the site-of-service criteria are not met. Hospital outpatient infusion may be considered medically necessary for the initial course or re-initiation after ≥6 months, when no outpatient infusion center exists within 50 miles or no contracted home infusion agency will travel, or when the individual has clinical conditions that increase infusion risk (for example symptomatic cardiac arrhythmia, significant respiratory disease with FVC ≤40%, unstable renal function, difficult vascular access, acute mental status changes, or prior severe adverse drug reactions/anaphylaxis). An exception also exists for severe cytokine release syndrome when criteria are met.

Therapies that target mast-cell or histamine-mediated mechanisms are not appropriate for treatment of HAE acute attacks. The policy and clinical guidance emphasize that HAE attacks are driven by kallikrein–bradykinin pathways, so agents such as antihistamines, epinephrine, and corticosteroids do not address the underlying mechanism and are not effective as HAE-specific treatment.

Previous policy language requiring a trial of danazol (or another androgen) for adult males was removed in the 2024 update. The policy no longer requires an androgen trial as a prerequisite for coverage of agents such as Haegarda, Orladeyo, Takhzyro, and Cinryze for adult males.

Initial Therapy and Preference

inv-34: Initial therapy — initial authorization criteria for acute treatment and prophylaxis

Initial authorization criteria for acute treatment and prophylaxis

Acute treatment eligibility: Agent‑specific acute treatment requires documented HAE laboratory confirmation (low C4 ± C1‑INH antigenic/function as appropriate) and the clinical features described in policy; agents have minimum age requirements for acute use (e.g., generic icatibant/Firazyr generally ≥18 years except where specified; Ruconest ≥13 years).

Prophylaxis eligibility: Long‑term prophylaxis agents require documented HAE laboratory confirmation, clinical features, and one or more qualifying conditions such as attack frequency (e.g., ≥1 attack per month over 6 months), pregnancy, or recent laryngeal attack; age and dose limits are agent‑specific.

inv-35: Initial therapy preferences — guideline-based recommendations for initial choices

Guideline‑based recommendations to inform initial agent selection

Continuation and Reauthorization

inv-37: Continuation/Reauthorization

Reauthorization requirements for ongoing therapy

Reauthorization criteria: Reauthorization may be approved up to 12 months if initial criteria are met and the individual has shown and continues to show a reduction in baseline frequency of attacks for long‑term prophylaxis drugs.

inv-38: Lanadelumab continuation/maintenance

Lanadelumab continuation and maintenance considerations

Lanadelumab maintenance dosing: Maintenance dosing evaluated is 300 mg subcutaneously every 2 weeks (300 mg SC Q2W) with demonstrated reduction in monthly attack rate versus placebo in the HELP trial; safety assessed up to 26 weeks.300 mg SC Q2W

Efficacy and safety data referenced from phase 3 HELP study.

Step Therapy and Sequencing Rules

Step	Requirement	Applies to / Limitations
1
Trial of generic icatibant required prior to coverage of certain prophylactic or acute HAE agents (documented trial and inadequate response or intolerance)
Applies to adults (clarified to individuals >=18 years old and not currently pregnant per 2025 update); requirement referenced for agents including Haegarda, Orladeyo, Takhzyro, and select acute agents

Recommendation	Guideline detail	Coverage implication
First-line escalation
WAO/EAACI guideline recommends C1‑INH products, lanadelumab, and berotralstat as first‑line options for long‑term prophylaxis; androgens are second‑line and contraindicated in pregnancy and to be avoided in certain pediatric populations
Policy aligns with guideline preference: C1‑INH, lanadelumab, and berotralstat favored as initial long‑term prophylaxis; androgens reserved as second‑line and subject to pregnancy/age cautions

Step	Requirement	Applies to / Limitations
1
Trial of generic icatibant (historically Sajazir when listed) required before coverage of specified acute agents (Berinert, Kalbitor, Ruconest and others as noted)
Clarified in 2025 that the generic icatibant requirement applies to individuals aged 18 years or older who are not currently pregnant; historical references to Sajazir removed as preferred in 2025 update

Billing and Coding

HCPCS / J-codes listedHCPCS

J0593	Injection, lanadelumab-flyo (Takhzyro), mg
J0596	Injection; C1 esterase inhibitor (recombinant), Ruconest; 10 units
J0597	Injection; C-1 esterase inhibitor (human), Berinert, 10 units
J0598	Injection, C-1 esterase inhibitor (human), Cinryze, 10 units
J0599	Injection, c-1 esterase inhibitor (human), (Haegarda), 10 units
J1290	Injection, ecallantide (Kalbitor), mg
J1744	Injection; icatibant; mg
J3590	Unclassified biologics (use to report: Andembry and Dawnzera)

HCPCS / billing codes mentionedHCPCS

J0593	HCPCS code added (document notes coding updates)
J0596	HCPCS code referenced in history
J0599	HCPCS code referenced in history
J3590	HCPCS code referenced for Andembry and Dawnzera (and later additions)

Minimum age for site-of-service medical necessity

Minimum age (site-of-service medical necessity)>= 13 years

Applies toSite-of-service medical necessity reviews for IV/injectable HAE therapies (hospital outpatient, infusion center, physician office, home)

RationalePediatric administration complexities: physiologic, developmental, equipment and behavioral considerations

Age indication for Haegarda

Haegarda labeled age updateCoverage criteria updated to include patients up to 26 years of age (documented in 2020 history)

Referenced prescribing informationHaegarda (C1 esterase inhibitor subcutaneous [human]) prescribing information revised January 2022

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization and Approval Length

Prior authorization is required for drugs listed in this policy. Initial authorizations for drugs listed in the policy may be approved up to 3 months; non-formulary exception reviews may be approved up to 12 months. Reauthorization and non-formulary exception reviews may be approved up to 12 months when conditions are met and the member has shown and continues to show a reduction in baseline attack frequency for long-term prophylaxis agents. The medications listed in this policy are subject to the product's FDA dosage and administration prescribing information.

Initial authorization: up to 3 months (standard reviews)
Non-formulary exception review: may be approved up to 12 months
Reauthorization: may be approved up to 12 months when clinical benefit demonstrated
Prescribers must follow the product's FDA dosing and administration

Denial Risk

Denial Triggers

Quantity Limits and Dosing

Ekterly quantity limits

Ekterly per-24-hour limit1,200 mg per 24 hours

Ekterly per-30-day limit2,400 mg every 30 days

Maximum recommended per attack1,200 mg in any 24-hour period (documented as maximum per HAE attack)

Ruconest quantity limits

Ruconest daily limit150 mg per day

Indication contextDose limit applies when Ruconest is used for acute treatment or prophylaxis per criteria

Benefit assignmentRuconest managed under the medical benefit

Place of Service Guidance

Billing Rule

Prefer office, infusion center, or home infusion; reserve hospital outpatient

Preferred medically necessary administration sites include physician office, infusion center, or home infusion when appropriate and cost‑effective; hospital outpatient infusion is reserved for initial courses, re‑initiation after ≥6 months, lack of nearer resources, or significant clinical risk factors.

Preferred: physician office, infusion center, home infusion
Hospital outpatient setting: initial course, re‑initiation after ≥6 months, no nearby infusion center or home agency, or clinical risk factors

Note

SOS review applies only to patients ≥13 years

Site‑of‑service medical necessity review is limited to individuals 13 years of age and older due to pediatric administration considerations; confirm age before initiating an SOS review.

Definitions

Hereditary angioedema (HAE) is an inherited disorder characterized by unpredictable, potentially life‑threatening episodes of localized swelling (angioedema), which can involve the extremities, face, gastrointestinal tract, and upper airway. HAE is commonly caused by deficiency or dysfunction of C1 esterase inhibitor (C1‑INH) leading to unregulated activation of contact system proteases and overproduction of bradykinin. Management includes on‑demand treatment of acute attacks and short‑ or long‑term prophylaxis; guideline-recommended acute therapies include intravenous C1‑INH, ecallantide, or icatibant, and first‑line long‑term prophylaxis options include C1‑INH products, lanadelumab, and berotralstat.

HAE definition key value

DefinitionHereditary angioedema (HAE) is an inherited disorder causing unpredictable, intermittent edema and inflammation that can be life threatening (e.g., laryngeal swelling)

Typical prevalenceAffects about 1 in 50,000 people

Clinical featuresRecurrent angioedema without wheals/urticaria, recurrent abdominal attacks, positive family history, failure to respond to antihistamines/glucocorticoids/epinephrine

Policy Summary

PayerPremera Bluecross

PolicyHereditary angioedema drug coverage and site-of-service criteria

Policy CodePolicy N/A

Change TypeMaterial updates to coverage criteria, step-therapy, age indications, and site-of-service exceptions

Effective DateOct 3, 2025

Next Review DateN/A

Key ActionSubmit prior authorization with office visit notes and laboratory results (low C4 and C1‑INH testing) to document medical necessity.

SourceLink

On This Page

inv-36: Initial acute therapy — initial acute treatment sequencing where specified

When sequencing of acute agents is specified

Initial acute agent requirement: Policy includes provisions that a trial of generic icatibant (or Sajazir historically) is required prior to coverage of certain other acute agents (e.g., Berinert, Kalbitor, Ruconest) for eligible adults, with later clarification limiting this requirement to individuals ≥18 years who are not currently pregnant.applies to adults >=18 years not currently pregnant

See policy history for timing of changes and clarifications.

Initial authorization duration: Initial authorizations for drugs listed in this policy may be approved up to 3 months; non‑formulary exception reviews may be approved up to 12 months.<=3 months (standard) or <=12 months (non‑formulary exception)

Policy history and prior authorization section document these limits.

Reauthorization duration: Reauthorization authorizations may be approved up to 12 months when reauthorization criteria are met, including documented reduction in baseline attack frequency for prophylactic agents.<=12 months

Clarified in 2025 update.

Documentation Required

Required Clinical Documentation

Medical record documentation must be submitted and include office visit notes and applicable laboratory test results that demonstrate the member meets medical necessity criteria.

Office visit notes containing relevant history and physical exam
Applicable laboratory testing results (e.g., C4, C1-INH antigenic and functional levels)
Documentation of prior acute treatments used and frequency of attacks (for prophylaxis criteria)
For pregnancy or laryngeal attack exceptions, include supporting documentation

Step Therapy

Step Requirement for Certain Agents

Certain agents require step therapy before coverage is approved. Where step requirements apply, documentation of trial and inadequate response or intolerance to the preferred agent(s) is required.

Trial and inadequate response or intolerance to generic icatibant (or Sajazir when applicable) is required for Berinert, Kalbitor, Ruconest, Firazyr in individuals aged ≥18 years who are not currently pregnant
Danocrine (danazol) or other androgen trial removed as requirement for certain agents (Haegarda, Orladeyo, Takhzyro, Cinryze) per 2024 update
When step therapy is required, include dates, dose, duration, and reason for discontinuation in records

Note

Therapy Preference Guidance (Guideline Sequencing)

Guideline-based therapy preference should be followed when available. WAO/EAACI guidance favors C1-INH products, lanadelumab, and berotralstat as first-line long-term prophylaxis and IV C1-INH, ecallantide, or icatibant for acute attacks. Pregnancy and pediatric recommendations should be observed.

First-line long-term prophylaxis: C1-INH (plasma-derived), lanadelumab, berotralstat
First-line acute treatment: IV C1-INH, ecallantide, or icatibant
Prefer plasma-derived C1-INH in pregnancy and lactation
Children: use C1-INH or icatibant for acute attacks in those under 12

Step Therapy

Generic Icatibant Step Therapy

Generic icatibant (and Sajazir where noted) is used as the step-therapy preferred acute agent for certain drugs; for adults (≥18 years) who are not pregnant, a documented trial of generic icatibant is required before coverage of specified agents.

Generic icatibant step applies to Berinert (pdC1-INH), Kalbitor (ecallantide), Ruconest (rhC1-INH), Firazyr (icatibant) where noted
Requirement applies to individuals aged 18 years or older who are not currently pregnant
Documentation must show trial, dose, duration, and inadequate response or intolerance

Prior Authorization

Prescribing Information and Exception Duration

When requesting site-of-service review or exceptions, include prescribing information and note that non-formulary exceptions may be approved up to 12 months. Prescribers should follow FDA dosing and administration; exceptions to SOS may exist for CRS treatment or for Alaska fully-insured members as noted.

Non-formulary exception reviews: may be approved up to 12 months
Follow the product's FDA dosing and administration prescribing information
Site-of-service requirements do not apply to Alaska fully-insured members per Alaska HB 226
Exception to SOS requirements may apply for cytokine release syndrome (CRS) treatment

Note

SOS rules generally apply; exclude Alaska fully‑insured members and note CRS exception

Site‑of‑service criteria generally apply but do not apply to Alaska fully‑insured members pursuant to Alaska HB 226; note also the policy exception for certain cytokine release syndrome (CRS) treatments.

Alaska fully‑insured members: SOS criteria do not apply (follow infusion/injection drug medical necessity only)
Exception exists for certain individuals receiving treatment for CRS

HAE long-term prophylaxis definition

DefinitionHAE long-term prophylaxis refers to preventive therapy intended to reduce the frequency and severity of acute angioedema attacks (examples: lanadelumab, berotralstat, and C1-INH products)

Authorization requirementsProphylaxis agents require documented HAE laboratory values, clinical features, and additional qualifying conditions such as attack frequency, pregnancy, or recent laryngeal attack

Outcomes for reauthorizationReauthorization may be approved up to 12 months when the individual shows and continues to show a reduction in baseline attack frequency